Kiniksa Pharmaceuticals International (KNSA) total liabilities

Total liabilities · fiscal 2025
$196.03M

Kiniksa Pharmaceuticals International (KNSA) had total liabilities of $196.03M at the end of fiscal 2025 (December 31, 2025). That is 37.9% higher than the $142.12M of fiscal 2024. Figures as of 19 Nov 2026, 11:36 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$196.03M
Change on fiscal 2024
+37.9%
Growth, 5 years
+39.2% a year
Highest on record
$196.03Mfiscal 2025
Lowest on record
$17.43Mfiscal 2017
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Kiniksa Pharmaceuticals International total liabilities, in more detail

Over the five fiscal years to 2025 total liabilities grew at a compound 39.2% a year. Across the 9 fiscal years on record (2017–2025), the highest was $196.03M in fiscal 2025 and the lowest $17.43M in fiscal 2017.

History · 9 fiscal years

Total liabilities by fiscal year

Kiniksa Pharmaceuticals International total liabilities, year by year

Kiniksa Pharmaceuticals International (KNSA) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$196.03M 37.9% up
2024$142.12M 62.5% up
2023$87.48M 37.7% up
2022$63.52M 33.0% up
2021$47.76M 27.3% up
2020$37.53M 28.9% up
2019$29.11M 31.8% down
2018$42.70M 145.0% up
2017$17.43M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

Total liabilities at health care companies of similar size

Total liabilities of Kiniksa Pharmaceuticals International and comparable companies
CompanyTotal liabilitiesFiscal year
Alkermes ALKS$667.70M2025
PACS Group PACS$4.63B2025
Kiniksa Pharmaceuticals International KNSA$196.03M2025
ImmunityBio IBRX$1.00B2025
Cytokinetics CYTK$2.08B2025
ABIVAX ABVX€129.14M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on KNSA

Kiniksa Pharmaceuticals International, figure by figure

Kiniksa Pharmaceuticals International (KNSA) overview: price, valuation and scorecardAll health care companies by market value

Kiniksa Pharmaceuticals International total liabilities: questions and answers

How large are Kiniksa Pharmaceuticals International's total liabilities?

Kiniksa Pharmaceuticals International (KNSA) had total liabilities of $196.03M at the end of fiscal 2025 (December 31, 2025). That is 37.9% higher than the $142.12M of fiscal 2024.

What is the growth rate of Kiniksa Pharmaceuticals International's total liabilities?

Over the five fiscal years to 2025 total liabilities grew at a compound 39.2% a year.

What are the highest and lowest total liabilities figures on record for Kiniksa Pharmaceuticals International?

Across the 9 fiscal years on record (2017–2025), the highest was $196.03M in fiscal 2025 and the lowest $17.43M in fiscal 2017.

How is Kiniksa Pharmaceuticals International's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Kiniksa Pharmaceuticals International it is on record here for 9 fiscal years, 2017 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Kiniksa Pharmaceuticals International (KNSA) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/KNSA/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.